Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
据周三晚报导,福修康美药业的Tazemetostat用于复发/难治性滤泡性淋巴瘤已获中国新药申请受理并获得优先审评。
Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China
据周三晚报导,福修康美药业的Tazemetostat用于复发/难治性滤泡性淋巴瘤已获中国新药申请受理并获得优先审评。